The DOI matches its Crossref record, with a small difference in title or year; 195 of the 196 references it cites were found in a registry or an index.
Omics and Drug Response
Abstract
A new generation of technologies commonly named omics permits assessment of the entirety of the components of biological systems and produces an explosion of data and a major shift in our concepts of disease. These technologies will likely shape the future of health care. One aspect of these advances is that the data generated document the uniqueness of each human being in regard to disease risk and treatment response. These developments have reemphasized the concept of personalized medicine. Here we review the impact of omics technologies on one key aspect of personalized medicine: the individual drug response. We describe how knowledge of different omics may affect treatment decisions, namely drug choice and drug dose, and how it can be used to improve clinical outcomes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of particular clinical relevance, CYP3A4 is responsible for metabolizing nearly 50% of commonly prescribed medications (65, 66).”
From Case Report: Integrating clinical presentation and genetic analysis in P450 oxidoreductase deficiency: a novel mutation and systematic review (2026) · cites this paper as [65]
Citations
Cites
1 retracted
Antoine, D. J., Jenkins, R. E., Dear, J. W., Williams, D. P., McGill, M. R., Sharpe, M. R., Craig, D. G. N., Simpson, K. J., Jaeschke, H., & Park, B. K. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.019 · Cited by 307
RetractedRNA-Seq: a revolutionary tool for transcriptomics
Wang, Z., Gerstein, M., & Snyder, M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2484 · Cited by 13,174
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
A map of human genome variation from population-scale sequencing.
The 1000 Genomes Project Consortium (2010) · Nature · doi:10.1038/nature09534 · Cited by 7,877
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
Biomarkers Definitions Working Group (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,771
Alternative isoform regulation in human tissue transcriptomes
Wang, E. T., Sandberg, R., Luo, S., Khrebtukova, I., Zhang, L., Mayr, C., Kingsmore, S. F., Schroth, G. P., & Burge, C. B. (2008) · Nature · doi:10.1038/nature07509 · Cited by 5,181
Research works printed but not linked: 6
- Natl. Res. Counc., 2011, Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease
- Rappaport SM, 2011, Nucleic Acids Res., 21, 5
- 10.1038/nature10166 · DOI · Paper page
- Zhang W, 2010, Curr. Opin. Mol. Ther., 12, 695
- Rhea JM, 2011, MLO Med. Lab. Obs., 43, 10
- Blay J-Y, 2011, Semin. Oncol., 38, S3
Cited by
Sorted by citations
Analytical Methods in Untargeted Metabolomics: State of the Art in 2015
Alonso, A., Marsal, S., & Julià, A. (2015) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2015.00023 · Cited by 727
Genomic analyses identify distinct patterns of selection in domesticated pigs and Tibetan wild boars
Li, M., Tian, S., Jin, L. G., Zhou, G., Li, Y., Zhang, Y., Wang, T., Yeung, C. K. L., Chen, L., Ma, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2811 · Cited by 560
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
Ahmed, S., Zhou, Z. M., Zhou, J., & Chen, S. (2016) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.03.008 · Cited by 415
Worst, B. C., van Tilburg, C. M., Balasubramanian, G. P., Fiesel, P., Witt, R., Freitag, A., Boudalil, M., Previti, C., Wolf, S., Schmidt, S., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.009 · Cited by 338
Self-citationWolking, S., Schaeffeler, E., Lerche, H., Schwab, M. G., & Nies, A. T. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0267-1 · Cited by 313
Self-citation
Metadata
- Authors
- Meyer, U. A., Zanger, U. M., & Schwab, M.
- Affiliations
- University of Basel (CH)
- Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (DE)
- Universitätsklinikum Tübingen (DE)
- Venue
- Annual Review of Pharmacology and Toxicology
- Publisher
- Annual Reviews
- Published
- 2013-01-06
- Volume
- 53
- Issue
- 1
- Pages
- 475-502
- ISSN
- 0362-1642 (ISSN-L)
- 1545-4304
- OpenAlex
- W2098156682
- Cited by
- 157
- References
- 196
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 6 · 2023: 5 · 2022: 10 · 2021: 5 · 2020: 12 · 2019: 17 · 2018: 10 · 2017: 15 · 2016: 12 · 2015: 17 · 2014: 17 · 2013: 14
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Annual Review of Pharmacology and Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Robert Bosch Stiftung
- Bundesministerium für Bildung und Forschung
- National Institutes of Health
- National Human Genome Research Institute
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- omics technologies, drug response, personalized medicine, pharmacogenomics, drug selection, drug dosing, treatment response variability, clinical outcomes, precision medicine
- MeSH terms
- Animals, Humans, Pharmacogenetics, Genomics, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
